CCL5 elevation

Our findings suggest that PRELP induces the expression of MHC class I and CCL5 in melanoma, which might be involved in an enhanced T cell recruitment and immunogenicity associated with an improved patients' outcome. Therefore, PRELP might serve as a marker for predicting disease progression and its recovery could revert the tumorigenic phenotype, which represents a novel therapeutic option for melanoma.

Depletion experiments showed that CD4+ T lymphocytes and MHC-II+ (likely dendritic cells) cells were responsible for the antitumor response. mIF also evidenced significant interaction between CD4+ and CD11c+ cells.ConclusionThis study unveils the mechanisms underlying the antitumor response of the combination of dasatinib with immunotherapy in high YES1 SCLC models, highlighting the role of CD4 T lymphocytes and MHC-II+ cells in the therapeutic response.

CCL5 is a ligand for the CC motif receptor 5 (CCR5), for which a clinically approved inhibitor exists, namely Maraviroc...High CCL5 or CCR5 expression is associated with worse prognosis in low grade esophageal carcinomas. Implications: These data highlight the role of CCL5 in tumorigenesis and the therapeutic potential of targeting the CCL5-CCR5 axis in ESCC.

The therapy that can effectively activate effector T cells and inhibit MDSCs targeting chemokine networks might support the magnitude of TILs in liver tumors. The chemokine signatures in the CCL5-subtype are a valuable resource for future research to identify clinically relevant biomarkers.